F. Michael Yakes
Impact in
- Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Molecular Biology top 2%
- Mitochondrial Function and Pathology
- PI3K/AKT/mTOR signaling in cancer
- DNA Repair Mechanisms
Papers in
-
- PI3K/AKT/mTOR signaling in cancer 7
- Glycosylation and Glycoproteins Research 3
- Protein Degradation and Inhibitors 2
- Oncology 10
- HER2/EGFR in Cancer Research 5
- Cancer-related Molecular Pathways 4
- Co-authors
- Bennett Van Houten (3 shared papers)Carlos L. Arteaga (9 shared papers)Incheol Shin (2 shared papers)Christoph A. Ritter (2 shared papers)Stacy L. Moulder (3 shared papers)Roberto Bianco (2 shared papers)Federico Rojo (1 shared paper)José Baselga (1 shared paper)
- Journals
- Seminars in Oncology (3 papers)Cancer Research (2 papers)Proceedings of the National Academy of Sciences (2 papers)Molecular Cancer Therapeutics (1 paper)Nature Medicine (1 paper)
- Partner nations
- United StatesSpainUnited Kingdom
In The Last Decade
F. Michael Yakes
20 papers receiving 5.7k citations
F. Michael Yakes's Hit Papers
Peers
Comparison fields: 5 of 131
- Oncology 2.3k
- Molecular Biology 3.4k
- Hepatology 390
- Cancer Research 679
- Clinical Biochemistry 272
Countries citing papers authored by F. Michael Yakes
This map shows the geographic impact of F. Michael Yakes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Michael Yakes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Michael Yakes more than expected).
Fields of papers citing papers by F. Michael Yakes
This network shows the impact of papers produced by F. Michael Yakes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Michael Yakes. The network helps show where F. Michael Yakes may publish in the future.
Co-authors
The 25 scholars most cited alongside F. Michael Yakes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress Hit paper breakdown → | 1997 | 1496 |
| 2 | Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth Hit paper breakdown → | 2011 | 1036 |
| 3 | PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization Hit paper breakdown → | 2002 | 642 |
| 4 | Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Hit paper breakdown → | 2002 | 506 |
| 5 | Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. | 2001 | 465 |
| 6 | 2000 | 385 | |
| 7 | 2003 | 357 | |
| 8 | 2009 | 282 | |
| 9 | ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. | 2001 | 156 |
| 10 | 2015 | 146 | |
| 11 | 2013 | 102 | |
| 12 | 2002 | 76 | |
| 13 | 2002 | 67 | |
| 14 | 2001 | 67 | |
| 15 | 2002 | 45 | |
| 16 | CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis. | 2000 | 13 |
| 17 | 1998 | 11 | |
| 18 | Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis. | 2001 | 10 |
| 19 | 2014 | 1 | |
| 20 | 2001 | 1 |
About F. Michael Yakes
F. Michael Yakes is a scholar working on Molecular Biology, Oncology, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging and Biotechnology, having authored 20 papers that have together received 5.9k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (7 papers), HER2/EGFR in Cancer Research (5 papers), Cancer-related Molecular Pathways (4 papers), Cancer Mechanisms and Therapy (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Cancer Research and Treatments (3 papers), Glycosylation and Glycoproteins Research (3 papers) and Protein Degradation and Inhibitors (2 papers). The work is most often cited by research in Oncology (2.3k citations), Molecular Biology (3.4k citations), Hepatology (390 citations), Cancer Research (679 citations) and Clinical Biochemistry (272 citations). F. Michael Yakes has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Bennett Van Houten, Carlos L. Arteaga, Incheol Shin, Christoph A. Ritter, Stacy L. Moulder, Roberto Bianco, Federico Rojo, José Baselga, Andrei V. Bakin and Jean F. Simpson. Their work appears in journals such as Seminars in Oncology, Cancer Research, Proceedings of the National Academy of Sciences, Molecular Cancer Therapeutics and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.